The company expects to grant the initial buyers an option to buy up to an additional $90 million of notes.
Net proceeds will be used to repurchase a portion of the company's outstanding 4.00% convertible senior notes due 2026 and expand certain clinical development programs.
Price: 42.06, Change: -6.68, Percent Change: -13.71